Cost-effectiveness analysis of first-line gifitinib plus pemetrexed-platinum-based chemotherapy versus gifitinib monotherapy in EGFR-mutated NSCLC patients with brain metastases

Related articles

1. First real-world experience with 1L pembrolizumab and chemotherapy treatment for advanced triple-negative breast cancer in Poland: safety analysis and first survival outcomes from a multicenter cohort

   This article has 22 authors:

   1. Małgorzata Pieniążek
   2. Aleksandra Konieczna
   3. Katarzyna Świderska
   4. Iwona Danielewicz
   5. Roman Dubiański
   6. Karolina Winsko-Szczęsnowicz
   7. Agnieszka Roman
   8. Justyna Żubrowska
   9. Tomasz Ciszewski
   10. Natalia Cichowska-Cwalińska
   11. Wioleta Łabul
   12. Anna Górniak
   13. Joanna Pleskacz
   14. Ewa Wójcik
   15. Małgorzata Meluch
   16. Jakub Wronowicz
   17. Bogumiła Czartoryska-Arłukowicz
   18. Michał Jarząb
   19. Marek Jasiówka
   20. Aleksandra Łacko
   21. Renata Pacholczak-Madej
   22. Mirosława Püsküllüoğlu

2. Unprecedented 60-month progression-free survival with reduced-dose crizotinib in a patient with ROS1-rearranged lung squamous cell carcinoma: a case report and literature review

   This article has 4 authors:

   1. Citing Guo
   2. Qi Zhang
   3. Jia Liu
   4. Cuiyan Guo

3. Real-World Effectiveness of Cisplatin, 5-Fluorouracil, and Pembrolizumab Combination Therapy for Unresectable or Recurrent Esophageal Cancer

   This article has 9 authors:

   1. Yu Ueta
   2. Masanobu Nakajima
   3. Masaki Yoshimatsu
   4. Takahiro Ochiai
   5. Shuhei Takise
   6. Junki Fujita
   7. Masatoshi Nakagawa
   8. Shinji Morita
   9. Kazuyuki Kojima